$SLS They say the stock market prices in all available information, but as seen below when it comes to SLS it is Deaf, Dumb, and BLIND! With GPS in a phase 3 trial for the blood cancer AML it has a historic 75% chance of success. The expected value of SLS stock would therefore be (($1.05Billion x .75)/$25.2Million)) x $2.52 = $78.75 per share! Another graph that reflects the probability of a rare disease getting approved follows. This does not reflect the dual designation for an orphan disease which would improve the probability of approval!